[go: up one dir, main page]

DE60017924D1 - Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose - Google Patents

Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose

Info

Publication number
DE60017924D1
DE60017924D1 DE60017924T DE60017924T DE60017924D1 DE 60017924 D1 DE60017924 D1 DE 60017924D1 DE 60017924 T DE60017924 T DE 60017924T DE 60017924 T DE60017924 T DE 60017924T DE 60017924 D1 DE60017924 D1 DE 60017924D1
Authority
DE
Germany
Prior art keywords
incarrose
recombinant
liver
treatment
adenoviral vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017924T
Other languages
English (en)
Other versions
DE60017924T2 (de
Inventor
Borunda Juan Armendariz
Cordova Estuardo Aguilar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TGT Laboratories SA de CV
Original Assignee
TGT Laboratories SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MXPA/A/1999/008515A external-priority patent/MXPA99008515A/xx
Application filed by TGT Laboratories SA de CV filed Critical TGT Laboratories SA de CV
Application granted granted Critical
Publication of DE60017924D1 publication Critical patent/DE60017924D1/de
Publication of DE60017924T2 publication Critical patent/DE60017924T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60017924T 1999-09-17 2000-09-14 Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose Expired - Lifetime DE60017924T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXPA/A/1999/008515A MXPA99008515A (es) 1999-09-17 Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepática, renal, pulmonar y cicatrices hipertróficas
MX9908515 1999-09-17
PCT/MX2000/000035 WO2001021761A2 (es) 1999-09-17 2000-09-14 Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar y cicatrices hipertroficas

Publications (2)

Publication Number Publication Date
DE60017924D1 true DE60017924D1 (de) 2005-03-10
DE60017924T2 DE60017924T2 (de) 2006-03-30

Family

ID=19745116

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60017924T Expired - Lifetime DE60017924T2 (de) 1999-09-17 2000-09-14 Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
DE1221490T Pending DE1221490T1 (de) 1999-09-17 2000-09-14 Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1221490T Pending DE1221490T1 (de) 1999-09-17 2000-09-14 Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben

Country Status (12)

Country Link
US (3) US20030003077A1 (de)
EP (1) EP1221490B1 (de)
JP (1) JP4173663B2 (de)
AR (1) AR025692A1 (de)
AU (1) AU7322600A (de)
CA (1) CA2385538C (de)
CO (1) CO5420199A1 (de)
DE (2) DE60017924T2 (de)
ES (1) ES2183752T3 (de)
HK (1) HK1049860B (de)
PE (1) PE20010610A1 (de)
WO (1) WO2001021761A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391214A4 (de) * 2001-05-09 2006-05-17 Anges Mg Inc Gentransfer des angiogenen faktors bei hauterkrankungen
US7332469B2 (en) 2002-04-05 2008-02-19 Board Of Regents The University Of Texas System Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
EP1697505A1 (de) * 2003-12-23 2006-09-06 Schering Corporation Methoden zur herstellung von a549 zelllinien, die in serumfreiem medium in suspensionskultur stabil sind
CN1968717B (zh) * 2004-03-30 2013-08-21 延世大学教产学协力团 含有松弛素基因的基因送递系统和使用松弛素的药物组合物
US20080107630A1 (en) * 2006-04-10 2008-05-08 New York University Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus
KR102272213B1 (ko) 2014-07-08 2021-07-01 삼성전자주식회사 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도
EP4204555A4 (de) * 2020-08-28 2024-11-06 Carisma Therapeutics Inc. Modifizierte immunzellen für fibrose und entzündung

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
US6686198B1 (en) * 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU6883296A (en) * 1995-09-05 1997-03-27 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
ATE331786T1 (de) * 1996-04-25 2006-07-15 Takeda Pharmaceutical Matrix-metalloprotease
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6436393B1 (en) * 1998-04-29 2002-08-20 Guadalupe Bilbao Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof

Also Published As

Publication number Publication date
HK1049860A1 (en) 2003-05-30
DE60017924T2 (de) 2006-03-30
EP1221490B1 (de) 2005-02-02
JP4173663B2 (ja) 2008-10-29
EP1221490A2 (de) 2002-07-10
CA2385538C (en) 2007-11-06
US20050201984A1 (en) 2005-09-15
US8043855B2 (en) 2011-10-25
US20040156827A1 (en) 2004-08-12
HK1049860B (en) 2006-02-24
JP2004500040A (ja) 2004-01-08
DE1221490T1 (de) 2003-05-28
AR025692A1 (es) 2002-12-11
ES2183752T1 (es) 2003-04-01
WO2001021761A3 (es) 2001-09-07
US7858368B2 (en) 2010-12-28
CO5420199A1 (es) 2004-07-30
AU7322600A (en) 2001-04-24
CA2385538A1 (en) 2001-03-29
PE20010610A1 (es) 2001-05-25
WO2001021761A2 (es) 2001-03-29
ES2183752T3 (es) 2005-07-16
US20030003077A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69927128D1 (de) Verwendung von topisch applizierbaren Gerinnungsmaterial
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE69939575D1 (de) Entdeckung von Diensten in unmittelbarer Nähe
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
EP1030819A4 (de) Immunogene konjugierte polypeptide für die behandlung von herpes-simplex virus
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition